Lumida
/DMAC
⌘K
DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc

DMAC
$7.30USD↑+2.38%+0.17 today

MARKET CAP

393.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $8

52W RANGE

$4
$10

AI Summary

Stalk
TrimMedium

DMAC is in a Stage 4 decline despite a long-term uptrend, with a dominant lower high/low structure driving medium-term bearish bias. Price rallies have been rejected at declining EMAs and the 50-DMA, indicating supply control. A short-term uptick above EMAs reduces immediate sell timing, suggesting deferred execution. Trimming into resistance zones aligns with structural downtrend while awaiting clearer follow-through.

  • ↑Phase 2 preeclampsia trial interim shows on-target mechanistic response.
  • ↑Cash increased to $59.9 M, funding operations through 2027.
  • ↓Net cash used jumped to $29.1 M in FY 2025, cutting runway to Q3 2026.
Full analysis →
Insider Trades1 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Nov 16, 2023BuyDMACDavid J. WambekeChief Business Officer20,000$2.46$393.3M-29.94%+100.00%$49.2K+3.94%—Trim